Vasodilator Effect of Glucagon: Receptorial Crosstalk Among Glucagon, GLP-1, and Receptor for Glucagon and GLP-1

被引:21
作者
Selley, E. [1 ,2 ]
Kun, S. [1 ,2 ]
Szijarto, I. A. [3 ,4 ]
Kertesz, M. [1 ,2 ]
Wittmann, I. [1 ,2 ]
Molnar, G. A. [1 ,2 ]
机构
[1] Univ Pecs, Dept Med 2, Pecs, Hungary
[2] Univ Pecs, Nephrol Ctr, Pecs, Hungary
[3] Charite Campus Virchow Klinikum, Med Clin Nephrol & Internal Intens Care, Berlin, Germany
[4] Max Delbruck Ctr Mol Med, ECRC, Berlin, Germany
关键词
aortic rings; glucagon; GLP-1; vasodilatation; INSULIN-INDUCED RELAXATION; SMOOTH-MUSCLE-CELLS; FATTY LIVER-DISEASE; ANTIDIABETIC AGENTS; MECHANISM; ARTERIES; SECRETION; CHANNELS; INCREASE; INJURY;
D O I
10.1055/s-0042-101794
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Glucagon is known for its insulin-antagonist effect in the blood glucose homeostasis, while it also reduces vascular resistance. The mechanism of the vasoactive effect of glucagon has not been studied before; thereby we aimed to investigate the mediators involved in the vasodilatation induced by glucagon. The vasoactive effect of glucagon, insulin, and glucagon-like peptide-1 was studied on isolated rat thoracic aortic rings using a wire myograph. To investigate the mechanism of the vasodilatation caused by glucagon, we determined the role of the receptor for glucagon and the receptor for GLP-1, and studied also the effect of various inhibitors of gasotransmitters, inhibitors of reactive oxygen species formation, NADPH oxidase, prostaglandin synthesis, protein kinases, potassium channels, and an inhibitor of the Na+/Ca2+-exchanger. Glucagon causes dose-dependent relaxation in the rat thoracic aorta, which is as potent as that of insulin but greater than that of GLP-1 (7-36) amide. Vasodilatation by GLP-1 is partially mediated by the glucagon receptor. The vasodilatation due to glucagon evokes via the glucagon-receptor, but also via the receptor for GLP-1, and it is endothelium-independent. Contribution of gasotransmitters, prostaglandins, the NADPH oxidase enzyme, free radicals, potassium channels, and the Na+/Ca2+ -exchanger is also significant. Glucagon causes dose-dependent relaxation of rat thoracic aorta in vitro, via the receptor for glucagon and the receptor for GLP-1, while the vasodilatation evoked by GLP-1 also evolves partially via the receptor for glucagon, thereby, a possible crosstalk between the 2 hormones and receptors could occur.
引用
收藏
页码:476 / 483
页数:8
相关论文
共 50 条
  • [1] Glucagon, GLP-1 and Thermogenesis
    Gonzalez-Garcia, Ismael
    Milbank, Edward
    Dieguez, Carlos
    Lopez, Miguel
    Contreras, Cristina
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (14)
  • [2] Glucagon-like peptide 1 (GLP-1)
    Mueller, T. D.
    Finan, B.
    Bloom, S. R.
    D'Alessio, D.
    Drucker, D. J.
    Flatt, P. R.
    Fritsche, A.
    Gribble, F.
    Grill, H. J.
    Habener, J. F.
    Holst, J. J.
    Langhans, W.
    Meier, J. J.
    Nauck, M. A.
    Perez-Tilve, D.
    Pocai, A.
    Reimann, F.
    Sandoval, D. A.
    Schwartz, T. W.
    Seeley, R. J.
    Stemmer, K.
    Tang-Christensen, M.
    Woods, S. C.
    DiMarchi, R. D.
    Tschoep, M. H.
    MOLECULAR METABOLISM, 2019, 30 : 72 - 130
  • [3] Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
    Seghieri, Marta
    Christensen, Alexander S.
    Andersen, Andreas
    Solini, Anna
    Knop, Filip K.
    Vilsboll, Tina
    FRONTIERS IN ENDOCRINOLOGY, 2018, 9
  • [4] GLP-1/glucagon receptor co-agonism for treatment of obesity
    Miguel A. Sánchez-Garrido
    Sara J. Brandt
    Christoffer Clemmensen
    Timo D. Müller
    Richard D. DiMarchi
    Matthias H. Tschöp
    Diabetologia, 2017, 60 : 1851 - 1861
  • [5] The mediation by GLP-1 receptors of glucagon-induced insulin secretion revisited in GLP-1 receptor knockout mice
    Ahren, Bo
    Yamada, Yuichiro
    Seino, Yutaka
    PEPTIDES, 2021, 135
  • [6] GLP-1/glucagon receptor co-agonism for treatment of obesity
    Sanchez-Garrido, Miguel A.
    Brandt, Sara J.
    Clemmensen, Christoffer
    Mueller, Timo D.
    DiMarchi, Richard D.
    Tschoep, Matthias H.
    DIABETOLOGIA, 2017, 60 (10) : 1851 - 1861
  • [7] A Dual GLP-1/GIP Receptor Agonist Does Not Antagonize Glucagon at Its Receptor but May Act as a Biased Agonist at the GLP-1 Receptor
    Al-Zamel, Noura
    Al-Sabah, Suleiman
    Luqmani, Yunus
    Adi, Lobna
    Chacko, Siby
    Schneider, Tom Dario
    Krasel, Cornelius
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (14)
  • [8] Design of novel Xenopus GLP-1-based dual glucagon-like peptide 1 (GLP-1)/glucagon receptor agonists
    Jiang, Neng
    Jing, Lin
    Li, Qing
    Su, Sibiao
    Yang, Qimeng
    Zhou, Feng
    Chen, Xinyu
    Han, Jing
    Tang, Chunli
    Tang, Weizhong
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 212
  • [9] Nonconventional glucagon and GLP-1 receptor agonist and antagonist interplay at the GLP-1 receptor revealed in high-throughput FRET assays for cAMP
    Chepurny, Oleg G.
    Matsoukas, Minos-Timotheos
    Liapakis, George
    Leech, Colin A.
    Milliken, Brandon T.
    Doyle, Robert P.
    Holz, George G.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2019, 294 (10) : 3514 - 3531
  • [10] Allosteric Modulation of the Activity of the Glucagon-like Peptide-1 (GLP-1) Metabolite GLP-1 9-36 Amide at the GLP-1 Receptor
    Li, Naichang
    Lu, Jing
    Willars, Gary B.
    PLOS ONE, 2012, 7 (10):